Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Adana
Clinical trial register · Turkey

Clinical Trials in Adana, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Turkey and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5418 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5418
Studies in scope
all four open statuses
2461
Recruiting now
open to new participants
548
Lead sponsors
across recruiting studies
Top sites
Ankara 16 Adana 14 Istanbul 10 Afyonkarahisar 6 Edirne 6
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC42 AstraZeneca36 Cukurova University28 Eli Lilly and Company21 Hoffmann-La Roche16 Clear sponsor filter
Site location
Ankara16 Adana14 Istanbul10 Afyonkarahisar6 Edirne6
All 42 locations
Target enrolment
to

Trials with a site in Adana

14 of 5418 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Turkey
Start
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Istanbul, Kayseri, Adana, Adapazarı/Turkiye, Afyonkarahisar, Ankara, Çanakkale/Türkiye, Eskişehir
2026-10-26
Recruiting
Novo Nordisk A/S
Phase 3
1,778
Kayseri, Adana, Adana /yüreği̇r, Adapazarı/Turkiye, Afyonkarahisar, Ankara, Gaziantep, Istanbul
2026-08-24
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Adana, Adapazarı/Sakarya, Afyonkarahisar, Altınordu/Ordu, Ankara, Antalya, Bayraklı/İzmir, Bursa
2026-05-11
Recruiting
Novo Nordisk A/S
Phase 3
510
Adana, Ankara, Mersin
2025-02-17
Recruiting
Novo Nordisk A/S
Phase 3
480
Adana, Ankara, Mersin
2025-01-10
Recruiting
Novo Nordisk A/S
Phase 2
465
Kayseri, Adana, Ankara, Gaziantep, Istanbul, Izmir, Kocaeli
2024-12-02
Active, closed
Novo Nordisk A/S
Phase 3
673
Eskişehir, Adana, Afyonkarahisar, Ankara, Bursa, Edirne, Istanbul, Kayseri
2024-04-01
Active, closed
Novo Nordisk A/S
Phase 3
7,101
Ankara, Istanbul, Eskişehir, Bursa, Adana, Afyonkarahisar, Edirne, Izmir
2023-03-01
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Ankara, Capa-ISTANBUL, Antalya, Adana, Bornova-IZMIR, Edirne
2023-02-13
Active, closed
Novo Nordisk A/S
Phase 3
3,400
Ankara, Sultangazi, Adana, Antalya, Hatay, Istanbul, Sivas
2022-11-01
Active, closed
Novo Nordisk A/S
Phase 3
153
Ankara, Adana, Izmir, Samsun
2022-03-24
Active, closed
Novo Nordisk A/S
Phase 3
1,205
Adana, Ankara, Bursa, Istanbul, Izmir, Kocaeli, Mersin, Yüreğir/Adana
2021-04-01
Active, closed
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
NCT04082429Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
DrugConcizumab
Novo Nordisk A/S
Phase 3
156
Ankara, Capa-ISTANBUL, Adana, Edirne, Izmir, Samsun
2019-11-13
Active, closed
Novo Nordisk A/S
Phase 3
134
Capa-ISTANBUL, Antalya, Adana
2019-10-21
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Turkish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-turkey/city/adana

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Turkey and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,418 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 14 of those studies with a site in Adana that also match the filters currently applied.

How many clinical trials are recruiting in Adana?

5 of the 14 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 1 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Adana), 14 studies
PhaseStudiesRecruitingShare
Phase 313492.9%
Phase 2117.1%

Most active sponsors

Lead sponsors with the most studies (Adana)
Lead sponsorStudiesRecruiting
Novo Nordisk A/S145
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.